Twinject competes in the epinephrine auto-injector market as a treatment for anaphylaxis. It is the only auto-injector with two inseparable doses of epinephrine in a single device. Twinject is light weight, small in size, easy to carry and has the smallest gauge needle on the market.
Twinject directly addresses a number of the short comings of other auto-injectors. Its innovative design provides the patient or caregiver an easy to use auto-injector with one of the easiest activation methodologies on the market. Twinject also uniquely addresses the need for patients to have a second dose readily available, if it becomes necessary.
Twinject represents the first innovation in the epinephrine market in over 25 years. It is a superior product compared to the current market leader in the U.S. Twinject does not require the competitor’s swing and jab technique in order to activate the injector. Patient surveys in the U.S. showed 9 out of 10 patients who use the leading competitor product preferred Twinject ‘press and hold’ activation sequence. When combined with a smaller gauge needle and the guaranteed availability of a second dose, Twinject should become the preferred product in most markets over time.
Strong IP surrounds Twinject in the United States, Germany, Spain, France, Great Britain, Italy, Canada, Poland, Portugal, and Russia.
Sciele is currently reaching out to selected potential partners for the commercialization of Twinject outside of North America. The preferred transaction would involve out licensing of the product for appropriate upfront, milestone payments and royalties. Sciele will provide finished product ready for labeling at a price to be determined.
Mr Greg Michael
Director
Business Development
Sciele Pharma Inc. acquires, develops, and markets prescription medicines within cardiovascular, obstetrical and gynaecological, paediatric and gastroenterological disorders
View profile© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
